Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its holdings in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 16.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 164,000 shares of the company’s stock after buying an additional 23,100 shares during the period. Renaissance Technologies LLC’s holdings in Immunocore were worth $4,945,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Public Employees Retirement System of Ohio grew its holdings in Immunocore by 24.2% during the first quarter. Public Employees Retirement System of Ohio now owns 31,253 shares of the company’s stock worth $942,000 after acquiring an additional 6,090 shares during the period. Sei Investments Co. raised its position in Immunocore by 21.7% in the first quarter. Sei Investments Co. now owns 61,260 shares of the company’s stock worth $1,847,000 after acquiring an additional 10,923 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Immunocore by 287.2% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 31,674 shares of the company’s stock valued at $955,000 after acquiring an additional 23,494 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in Immunocore in the fourth quarter valued at $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of Immunocore during the 4th quarter worth $763,000. 84.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Mizuho raised their target price on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Finally, Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $56.29.

Immunocore Stock Performance

Shares of NASDAQ:IMCR opened at $34.50 on Friday. The business has a 50-day moving average of $31.54 and a two-hundred day moving average of $31.33. The firm has a market capitalization of $1.76 billion, a PE ratio of -62.73 and a beta of 0.74. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $27.56 and a 12 month high of $40.71.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The firm had revenue of $115.93 million during the quarter, compared to analyst estimates of $148.44 million. As a group, research analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.08 earnings per share for the current year.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.